门冬氨酸-鸟氨酸治疗肝炎后脂肪肝的临床观察  

Clinical efficacy of aspartate-ornithine in treatment of hepatitis hepar adiposum

作　　者：曹宁芬[1] 袁迎春[1] 

机构地区：[1]宁夏医学院附属医院,宁夏银川750004

出　　处：《宁夏医学杂志》2008年第12期1108-1110,共3页Ningxia Medical Journal

摘　　要：目的观察门冬氨酸-鸟氨酸治疗肝炎后脂肪肝的临床疗效。方法117例肝炎后脂肪肝患者分成两组,对照组(60例)给予维生素C,治疗组(57例)给予门冬氨酸-鸟氨酸颗粒,口服3个疗程后,分别比较两组用药后的肝功能指标变化、血脂及临床症状的改变。结果治疗组治疗后,肝功能指标、血脂均明显降低,治疗组和对照组肝功能改善的总有效率分别为91.26%和22.81%,两组差异有统计学意义(P<0.05)。结论门冬氨酸-鸟氨酸治疗肝炎后脂肪肝疗效显著,且用药安全。Objective To assess the clinical efficacy of aspartate - ornithine in treatment of hepatitis hepar adiposum. Methods 117 patients was randomly divided into two group： treatment group （60 patients） and control groups （57 patients）, the treatment group received Aspartic acid - diaminovaleric acid and the control group received Vitamin C for 3 course of treatment. The changes of liver function in the two groups were compared. Results The levels of serum ALT, AST and γ- GT in the treatment group were all obviously reduced at the end point compared with the baseline. The levels of serum ALT in the control group was reduced, but levels of serum AST, γ - GT were no obviously changed. The total effective rate of the treatment group and the control group were 91.26% and 22. 81%, respectively （P 〈 0. 05）. Conclusion The aspartate - ornithine is an effective and safe remedy for the treatment of hepatitis hepar adiposum.

关 键 词：肝炎后脂肪肝 门冬氨酸-鸟氨酸 肝功能损害 

分 类 号：R575.5[医药卫生—消化系统]